Aberrant alternative splicing in breast cancer

被引:64
作者
Yang, Quan [1 ]
Zhao, Jinyao [1 ]
Zhang, Wenjing [1 ]
Chen, Dan [2 ]
Wang, Yang [1 ]
机构
[1] Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Peoples R China
[2] Dalian Med Univ, Affiliated Hosp 1, Dept Pathol, Dalian 116044, Peoples R China
基金
中国国家自然科学基金;
关键词
alternative splicing; breast cancer; splicing factors; drug resistance; cancer therapeutics; PRE-MESSENGER-RNA; ESTROGEN-RECEPTOR-ALPHA; SR PROTEIN-PHOSPHORYLATION; ANTISENSE OLIGONUCLEOTIDES; FACTOR MUTATIONS; PYRUVATE-KINASE; OVARIAN-CANCER; PROMOTES; RESISTANCE; EXPRESSION;
D O I
10.1093/jmcb/mjz033
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Alternative splicing is critical for human gene expression regulation, which plays a determined role in expanding the diversity of functional proteins. Importantly, alternative splicing is a hallmark of cancer and a potential target for cancer therapeutics. Based on the statistical data, breast cancer is one of the top leading causes of cancer-related deaths in women worldwide. Strikingly, alternative splicing is closely associated with breast cancer development. Here, we seek to provide a general review of the relationship between alternative splicing and breast cancer. We introduce the process of alternative splicing and its regulatory role in cancers. In addition, we highlight the functions of aberrant alternative splicing and mutations of splicing factors in breast cancer progression. Moreover, we discuss the role of alternative splicing in cancer drug resistance and the potential of being targets for cancer therapeutics.
引用
收藏
页码:920 / 929
页数:10
相关论文
共 141 条
  • [1] m6A: Signaling for mRNA splicing
    Adhikari, Samir
    Xiao, Wen
    Zhao, Yong-Liang
    Yang, Yun-Gui
    [J]. RNA BIOLOGY, 2016, 13 (09) : 756 - 759
  • [2] Splicing-factor alterations in cancers
    Anczukow, Olga
    Krainer, Adrian R.
    [J]. RNA, 2016, 22 (09) : 1285 - 1301
  • [3] SRSF1-Regulated Alternative Splicing in Breast Cancer
    Anczukow, Olga
    Akerman, Martin
    Clery, Antoine
    Wu, Jie
    Shen, Chen
    Shirole, Nitin H.
    Raimer, Amanda
    Sun, Shuying
    Jensen, Mads A.
    Hua, Yimin
    Allain, Frederic H. -T.
    Krainer, Adrian R.
    [J]. MOLECULAR CELL, 2015, 60 (01) : 105 - 117
  • [4] How Many Etiological Subtypes of Breast Cancer: Two, Three, Four, Or More?
    Anderson, William F.
    Rosenberg, Philip S.
    Prat, Aleix
    Perou, Charles M.
    Sherman, Mark E.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (08):
  • [5] [Anonymous], J NATL CANC I
  • [6] How did alternative splicing evolve?
    Ast, G
    [J]. NATURE REVIEWS GENETICS, 2004, 5 (10) : 773 - 782
  • [7] The potential role of estrogen receptor β2 in breast cancer
    Baek, Jong-Min
    Chae, Byung-Joo
    Song, Byung-Joo
    Jung, Sang-Seol
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2015, 14 : 17 - 22
  • [8] Established breast cancer risk factors and risk of intrinsic tumor subtypes
    Barnard, Mollie E.
    Boeke, Caroline E.
    Tamimi, Rulla M.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2015, 1856 (01): : 73 - 85
  • [9] Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
    Basaran, Gul A.
    Twelves, Chris
    Dieras, Veronique
    Cortes, Javier
    Awada, Ahmad
    [J]. CANCER TREATMENT REVIEWS, 2018, 63 : 144 - 155
  • [10] Pharmacology of Modulators of Alternative Splicing
    Bates, David O.
    Morris, Jonathan C.
    Oltean, Sebastian
    Donaldson, Lucy F.
    [J]. PHARMACOLOGICAL REVIEWS, 2017, 69 (01) : 63 - 79